Page 6,502«..1020..6,5016,5026,5036,504..6,5106,520..»

Smokers With Lung Cancer Have Tenfold Genetic Damage

Posted: Published on September 18th, 2012

Featured Article Academic Journal Main Category: Smoking / Quit Smoking Also Included In: Lung Cancer;Genetics Article Date: 17 Sep 2012 - 12:00 PDT Current ratings for: Smokers With Lung Cancer Have Tenfold Genetic Damage 3 (1 votes) Senior author Richard K. Wilson is director of The Genome Institute at Washington University School of Medicine in St. Louis in the US. He says in a media statement that none of his team was surprised that the genomes of smokers with lung cancer had more mutations than the genomes of never-smokers with the disease: "But it was surprising to see 10-fold more mutations. It does reinforce the old message - don't smoke," he adds. Within non-small cell there are also three further classifications: adenocarcinomas (usually found in an outer area of the lung); squamous cell carcinomas (usually found in the center of the lung next to a bronchus or air tube); and large cell carcinomas (these can occur in any part of the lung and tend to grow and spread faster than the other two classes). In their paper, the researchers describe how they carried out "whole-genome and transcriptome sequencing of tumor and adjacent normal tissue samples" from all 17 patients. Across … Continue reading

Comments Off on Smokers With Lung Cancer Have Tenfold Genetic Damage

As Genetic Sequencing Spreads, Excitement, Worries Grow

Posted: Published on September 18th, 2012

Enlarge David Paul Morris/Bloomberg via Getty Images Slides containing DNA sit in a bay waiting to be analyzed by a genome sequencing machine. Slides containing DNA sit in a bay waiting to be analyzed by a genome sequencing machine. Ever since James Watson and Francis Crick cracked the genetic code, scientists have been fascinated by the possibilities of what we might learn from reading our genes. But the power of DNA has also long raised fears such as those dramatized in the 1997 sci-fi film Gattaca which depicted a world where "a minute drop of blood determines where you can work, who you should marry, what you're capable of achieving." That was science fiction. Just three years later, President Bill Clinton announced that the once-futuristic dream of reading someone's entire genetic code their genome had become a reality. It took hundreds of scientists nearly a decade to painstakingly piece together the first real look at the entire human genetic blueprint. It cost $3 billion just to make that rough draft. Twelve years later, the cost of deciphering a person's genetic instructions has dropped faster than the price tag on flat-screen TVs. And the sequencing can be done much quicker. Over … Continue reading

Comments Off on As Genetic Sequencing Spreads, Excitement, Worries Grow

Cytomedix Shares Now Trading on OTCQX

Posted: Published on September 17th, 2012

GAITHERSBURG, Md., Sept. 17, 2012 /PRNewswire/ -- Cytomedix, Inc. (CMXI), a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell technologies, today announced that its common shares are now trading on the highest OTC marketplace, OTCQX, under the ticker symbol "CMXI." Cytomedix upgraded from OTCQB today to trade on the OTC market's prestigious marketplace, OTCQX. Investors can find current financial disclosure and real-time Level 2 quotes for the Company's common shares at http://www.otcmarkets.com. "We believe investors will appreciate the quality-controlled admission process, the transparent trading and easy access to company information that are hallmarks of the OTCQX," said Martin P. Rosendale, Chief Executive Officer of Cytomedix. C. K. Cooper & Company will serve as Cytomedix's Designated Advisor for Disclosure ("DAD") on OTCQX, and will be responsible for providing guidance on OTCQX requirements. About Cytomedix, Inc. Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. The Company's … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Cytomedix Shares Now Trading on OTCQX

Leading stem cell scientists to focus on diabetes, eye diseases at Cedars-Sinai symposium

Posted: Published on September 17th, 2012

Public release date: 17-Sep-2012 [ | E-mail | Share ] Contact: Nicole White nicole.white@cshs.org 310-423-5215 Cedars-Sinai Medical Center LOS ANGELES Sept. 17, 2012 Leading scientists and clinicians from across the nation will discuss the latest findings on potential stem cell treatments for diabetes and eye diseases at the second Cedars-Sinai Regenerative Medicine Scientific Symposium. WHO: Stem cell scientists, clinicians and industry leaders. The symposium is being hosted by the Cedars-Sinai Regenerative Medicine Institute, led by Clive Svendsen, PhD. The institute brings together basic scientists with specialist clinicians, physician scientists and translational scientists across multiple medical specialties to convert fundamental stem cell studies to therapeutic regenerative medicine. FEATURED RESEARCH: The symposium's morning session will feature an overview of the current state of stem cells and diabetes, including efforts to start the first clinical trials with stem cells for the treatment of diabetes. Other research to be presented includes an update on regenerative medicine approaches to treating macular degeneration, a progressive deterioration of the eye that causes gradual loss of vision. This will include an update from Gad Heilweil , MD, on a key, stem-cell clinical trial on macular degeneration at the University of California Los Angeles. WHEN: Sept. 21, 2012 8:30 … Continue reading

Comments Off on Leading stem cell scientists to focus on diabetes, eye diseases at Cedars-Sinai symposium

America Stem Cell, Inc. Awarded a Phase I STTR to Explore the Therapeutic Potential of Its Platform Technology (ASC …

Posted: Published on September 17th, 2012

SAN ANTONIO--(BUSINESS WIRE)-- America Stem Cell, Inc. (ASC) today announced that it has been awarded an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health. This grant will be conducted in collaboration with scientists at the Wake Forest Institute of Regenerative Medicine (WFIRM) in Winston-Salem, NC, and will explore the combination of two technologies: ASC-101 developed by America Stem Cell and amniotic fluid-derived stem cells discovered and pioneered by Dr. Shay Soker and colleagues at WFIRM. We will examine the effect of ASC-101-treated amniotic fluid-derived stem cells in an experimental model of compartment syndrome. Compartment syndrome results from a variety of injuries such as fractures, contusions, burns, trauma, post-ischemic swelling and blast injuries such as gunshot wounds. If not addressed quickly, it can lead to considerable loss of muscle tissue. Musculoskeletal disorders are the primary cause of disability in the United States with associated costs of more than $800 billion annually. In addition to civilian injuries, more than 42,000 soldiers have been injured since the beginning of the Iraq and Afghanistan wars: the majority of these injuries were musculoskeletal in nature. America Stem Cell has demonstrated … Continue reading

Comments Off on America Stem Cell, Inc. Awarded a Phase I STTR to Explore the Therapeutic Potential of Its Platform Technology (ASC …

Erasing Epilepsy: Stopping Storms In Your Brain

Posted: Published on September 17th, 2012

BACKGROUND: Epilepsy is when a person experiences repeated seizures, which are episodes of disturbed brain activity that causes changes in attention or behavior. There are various types of seizures that can range from simple staring spells to violent shaking and loss of alertness. The type of seizure depends on the part of the brain affected and the cause of the epilepsy. Epilepsy can be the result of medical condition or injury that affects the brain, although sometimes the cause is not known (idiopathic). A brain tumor, abnormal blood vessels in the brain, certain infections, dementia, and stroke are some things that can cause a person to develop epilepsy. The strange sensations that some people with epilepsy have before a seizure, such as tingling or smelling strange odors, are called auras. (Source: http://www.ncbi.nlm.nih.gov). TREATMENT: When epileptic seizures are the result of a brain tumor, abnormal blood vessels, or bleeding in the brain, surgery to treat these issues can possibly make the seizures stop. Other possible treatments include medications called anticonvulsants which can help limit the number of future seizures, but if a person misses the medication, it can cause a seizure and many of the drugs cannot be used by pregnant … Continue reading

Comments Off on Erasing Epilepsy: Stopping Storms In Your Brain

UCLA Center for Autism Research and Treatment Receives Multiple NIH Awards

Posted: Published on September 17th, 2012

Newswise The National Institutes of Health, recognizing UCLAs preeminence in both research and clinical care of children with autism, has announced multiple awards to the university as part of its Autism Centers of Excellence (ACE) research program. The UCLA Center for Autism Research and Treatment (CART) was the only NIH ACE Center in the country to be awarded renewed funding for the next five years. This continued funding will support ongoing research to examine how genes link to behavior, develop new clinical interventions for those severely affected, and seek to explain why there are more boys than girls with autism. The goal of this work is to understand the full range of Autism Spectrum Disorders (ASD), the brain disorder that causes a continuum of social deficits, communication difficulties, and cognitive delays. UCLAs CART will receive $10 million for its ongoing research into advancing treatments, the disorders genetics and biology, and improved diagnostics. New research will link genetic mutations to distinct patterns of brain development, structure, and function in children and adolescents with ASD. The research effort is led by Susan Bookheimer, the Joaquin Fuster Professor of Cognitive Neurosciences at UCLAs Semel Institute for Neuroscience and Human Behavior. The UCLA Center … Continue reading

Comments Off on UCLA Center for Autism Research and Treatment Receives Multiple NIH Awards

West Bloomfield's Preemie Growth Project believes micronutrients could help children with cerebral palsy

Posted: Published on September 17th, 2012

By KEVIN GRAHAM Special to The Oakland Press Caregiver Pat Dodge helps Dakota Jenkins, 7, shortly after he started taking supplements provided by nonprofit Preemie Growth Project, based in West Bloomfield. The micronutrient is believed to help those with cerebral palsy become less impaired. Submitted photo A new treatment previously used with premature babies is now being utilized to help fight cerebral palsy. According to the National Institutes of Health, cerebral palsy is a disease caused by injuries to the brain before, during or after birth. It causes neuromuscular problems, which might range from mild to severe in nature, and might affect all or part of the body. The Centers for Disease Control said an estimated 10,000 babies are born each year in the U.S. with cerebral palsy. The Preemie Growth Project, a nonprofit group based in West Bloomfield, is conducting test cases of a new micronutrient formula that it says could help children with cerebral palsy. The treatment was discovered at Childrens Hospital in Detroit last year. A 9-month-old boy diagnosed with cerebral palsy went from 12 pounds to 22 pounds in just 10 weeks, said Ida Briggs, the executive director and founder of the Preemie Growth Project. There … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on West Bloomfield's Preemie Growth Project believes micronutrients could help children with cerebral palsy

vasopharm's Traumatic Brain Injury Drug Exceeds Expectations in Phase IIa Exploratory Clinical Trial

Posted: Published on September 17th, 2012

WUERZBURG, Germany, September 17, 2012 /PRNewswire/ -- VAS203 demonstrates potential as safe and effective treatment vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients. Traumatic Brain Injury is caused when an external force impacts the head. It is a condition with high unmet medical need and is the leading cause of death and disability among young adults in the developed world. TBI accounts for more potential years of life lost than cancer and cardiovascular disease combined and there are currently no drugs available to treat this condition. The NOSTRA (NO-Synthase inhibition in TRAumatic brain injury) trial was a European, multicentre, placebo-controlled, double blind study with safety and tolerability as primary endpoints. The study employed 'in vivo' microdialysis to monitor pharmacodynamic and pharmacokinetic properties of the compound VAS203. VAS203 is a novel allosteric NO-synthase antagonist which interrupts the inducible nitric oxide process involved in brain swelling. In total, 32 patients with moderate to severe traumatic brain injury … Continue reading

Posted in Brain Injury Treatment | Comments Off on vasopharm's Traumatic Brain Injury Drug Exceeds Expectations in Phase IIa Exploratory Clinical Trial

Traumatic Brain Injury Drug Exceeds Expectations

Posted: Published on September 17th, 2012

VAS203 demonstrates potential as safe and effective treatment vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients. Traumatic Brain Injury is caused when an external force impacts the head. It is a condition with high unmet medical need and is the leading cause of death and disability among young adults in the developed world. TBI accounts for more potential years of life lost than cancer and cardiovascular disease combined and there are currently no drugs available to treat this condition. The NOSTRA (NO-Synthase inhibition in TRAumatic brain injury) trial was a European, multicentre, placebo-controlled, double blind study with safety and tolerability as primary endpoints. The study employed 'in vivo' microdialysis to monitor pharmacodynamic and pharmacokinetic properties of the compound VAS203. VAS203 is a novel allosteric NO-synthase antagonist which interrupts the inducible nitric oxide process involved in brain swelling. In total, 32 patients with moderate to severe traumatic brain injury were enrolled in three cohorts in six … Continue reading

Posted in Brain Injury Treatment | Comments Off on Traumatic Brain Injury Drug Exceeds Expectations

Page 6,502«..1020..6,5016,5026,5036,504..6,5106,520..»